<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156429">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01954992</url>
  </required_header>
  <id_info>
    <org_study_id>EP-GF-301</org_study_id>
    <nct_id>NCT01954992</nct_id>
  </id_info>
  <brief_title>Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eleison Pharmaceuticals LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eleison Pharmaceuticals LLC.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess whether glufosfamide provides additional survival benefit as
      compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already
      progressed or failed therapy on a gemcitabine based first line regimen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 3-6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from Randomization to death from any cause</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Second Line Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>glufosfamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glufosfamide: 4500 mg/m2 IV over 6 hours on Day 1 of each 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-FU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glufosfamide</intervention_name>
    <description>Glufosfamide: 4500 mg/m2 IV over 6 hours (¼  dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.</description>
    <arm_group_label>glufosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week</description>
    <arm_group_label>5-FU</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Pancreatic adenocarcinoma proven either by histology (surgical biopsy) or cytology
             (CT- or endoscopic-guided)

          -  Metastatic pancreatic cancer

          -  Disease progression during or after treatment with gemcitabine (alone or in
             combination with other agents; at regular, not radiosensitizing, doses)

          -  Measurable or nonmeasurable disease by RECIST criteria (at least one target or
             nontarget lesion)

          -  Recovered from reversible toxicities of prior therapy

          -  ECOG performance status 0-1

          -  All women of childbearing potential and all men must agree to use effective means of
             contraception (surgical sterilization or the use of barrier contraception with either
             a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into
             the study through 6 months after the last dose of chemotherapy

          -  Ability to understand the purposes and risks of the study and has signed a written
             informed consent form approved by the investigator's IRB/Ethics Committee

        Exclusion Criteria:

          -  More than one prior systemic therapy regimen for metastatic pancreatic cancer
             (radiosensitizing doses of 5-FU or gemcitabine at the time of initial radiotherapy do
             not count as a prior systemic therapy regimen)

          -  Hormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic
             antitumor therapy for pancreatic cancer within 14 days prior to Cycle 1 Day 1

          -  Insulin-dependent diabetes mellitus (patients with type 2 diabetes controlled with
             oral glucose lowering agents and the occasional use of insulin are permitted in the
             study)

          -  Symptomatic brain metastases (baseline CT scan is not required in asymptomatic
             patients)

          -  Active clinically significant infection requiring antibiotics

          -  Known HIV positive or active hepatitis B or C

          -  Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or
             4), particularly coronary artery disease, arrhythmias or conduction defects with risk
             of cardiovascular instability, uncontrolled hypertension, clinically significant
             pericardial effusion, or congestive heart failure

          -  No other active malignancies (other than treated non-melanoma skin cancer or treated
             in situ cancer) within the past year

          -  Major surgery within 3 weeks of the start of study treatment, without complete
             recovery

          -  Clinically significant abnormalities in laboratory test results (including complete
             blood count, chemistry panel including electrolytes, and urinalysis)

               -  Hemoglobin &lt;9 g/dL (may receive transfusion or erythropoietin to maintain)

               -  ANC &lt;1500/μL

               -  Platelet count &lt;100,000/μL

               -  Total bilirubin &gt; 1.5×ULN

               -  AST/ALT &gt; 2.5-fold above ULN (&gt;5-fold above ULN if liver metastases)

               -  Phosphorus &lt; LLN

               -  Potassium &lt; LLN

               -  Serum creatinine &gt; 2 mg/dL

               -  Creatinine clearance &lt; 60 mL/min (calculated by Cockcroft-Gault formula)

          -  Females who are pregnant or breast-feeding

          -  Participation in an investigational drug or device study within 14 days of the first
             day of dosing on this study

          -  Concomitant disease or condition that could interfere with the conduct of the study,
             or that would, in the opinion of the investigator, pose an unacceptable risk to the
             patient in this study

          -  Any medical history, concurrent disease or concomitant medication which could
             reasonably predispose the patient to renal insufficiency while on study treatment

          -  Contraindication or unwillingness to undergo multiple CT scans

          -  Unwillingness or inability to comply with the study protocol for any other reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Forrest Anthony, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eleison Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Forrest Anthony, MD, PhD</last_name>
    <phone>215-554-3530</phone>
    <email>forrest.anthony@eleison-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-652-6532</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Richy Agajanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rowland</last_name>
      <phone>813-745-1157</phone>
      <email>michael.rowland@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Richard Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RHHP/Hope Center</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelyn Bradfield</last_name>
      <phone>812-234-0098</phone>
      <email>Jacquelyn.bradfield@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Ashis K Chakrabarti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crescent City Research Consortium</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MaryAnn Ostroske</last_name>
      <phone>594-885-8220</phone>
      <email>Maryann.ostroske@wjmc.org</email>
    </contact>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Bongiorno</last_name>
      <phone>301-571-2016</phone>
      <email>NBongiorno@CCBDMD.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Stannard</last_name>
      <phone>603-650-9474</phone>
      <email>Maureen.G.Stannard@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Gregory Ripple, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton,</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <phone>330-417-8231</phone>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glufosfamide</keyword>
  <keyword>5-FU</keyword>
  <keyword>metastatic pancreatic adenocarcinoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
